CSNK1E/CTNNB1 Are Synthetic Lethal To TP53 in Colorectal Cancer and Are Markers for Prognosis

Neoplasia (United States)

Volumn 16, Issue 5, 2014, Pages 441-450

  Tiong, Khong Loon ^a,b   Chang, Kuo Ching ^c   Yeh, Kun Tu ^d,e   Liu, Ting Yuan ^f   Wu, Jia Hong ^c   Hsieh, Ping Heng ^c   Lin, Shu Hui ^d,g   Lai, Wei Yun ^b,h   Hsu, Yu Chin ^c   Chen, Jeou Yuan ^h   Chang, Jan Gowth ⁱ   Shieh, Grace S ^a,c  

^a ACADEMIA SINICA   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c INSTITUTE OF STATISTICAL SCIENCE   (Taiwan)

^d CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^e CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^f KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^g JEN TEH JUNIOR COLLEGE OF MEDICINE   (Taiwan)

^h INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

ⁱ CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CSNK1E PROTEIN; CTNNB1 PROTEIN; PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER PROGNOSIS; CANCER SURVIVAL; CELL VIABILITY; COLORECTAL CANCER; CONTROLLED STUDY; DNA REPLICATION; GENE EXPRESSION; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; ONCOGENE K RAS; ONCOGENE MYC; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; TUMOR XENOGRAFT;

EID: 84908506859     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2014.04.007     Document Type: Article

References (43)

1. Haggar FA, Boushey RP Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg 2009, 22:191-197.
2. Vogelstein B, Kinzler KW Cancer genes and the pathways they control. Nat Med 2004, 10:789-799.
3. Wheeler DL, Iida M, Kruser TJ, Nechrebecki MM, Dunn EF, Armstrong EA, Huang S, Harari PM Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab. Cancer Biol Ther 2009, 8:696-703.
4. Mani R, Onge RPS, Hartman JL, Giaever G, Roth FP Defining genetic interaction. Proc Natl Acad Sci U S A 2008, 105:3461-3466.
5. Tong AH, Evangelista M, Parsons AB, Xu H, Bader GD, Page N, Robinson M, Raghibizadeh S, Hogue CW, Bussey H, et al. Systematic genetic analysis with ordered arrays of yeast deletion mutants. Science 2001, 294:2364-2368.
6. Tong AH, Lesage G, Bader GD, Ding H, Xu H, Xin X, Young J, Berriz GF, Brost RL, Chang M, et al. Global mapping of the yeast genetic interaction network. Science 2004, 303:808-813.
7. Costanzo M, Baryshnikova A, Bellay J, Kim Y, Spear ED, Sevier CS, Ding H, Koh JL, Toufighi K, Mostafavi S, et al. The genetic landscape of a cell. Science 2010, 327:425-431.
8. Wong SL, Zhang LV, Tong AH, Li Z, Goldberg DS, King OD, Lesage G, Vidal M, Andrews B, Bussey H, et al. Combining biological networks to predict genetic interactions. Proc Natl Acad Sci U S A 2004, 101:15682-15687.
9. Zhong W, Sternberg PW Genome-wide prediction of C. elegans genetic interactions. Science 2006, 311:1481-1484.
10. Hartwell LH, Szankasi P, Roberts CJ, Murray AW, Friend SH Integrating genetic approaches into the discovery of anticancer drugs. Science 1997, 278:1064-1068.
11. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913-917.
12. Shen Y, Rehman FL, Feng Y, Boshuizen J, Bajrami I, Elliott R, Wang B, Lord CJ, Post LE, Ashworth A BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res 2013, 19:5003-5015.
13. Sessa C Update on PARP1 inhibitors in ovarian cancer. Ann Oncol 2011, 22(Suppl. 8):viii72-viii76.
14. Underhill C, Toulmonde M, Bonnefoi H A review of PARP inhibitors: from bench to bedside. Ann Oncol 2011, 22:268-279.
15. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P, Meylan E, Scholl C, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009, 462:108-122.
16. Luo J, Emanuele MJ, Li DN, Creighton CJ, Schlabach MR, Westbrook TF, Wong KK, Elledge SJ A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene. Cell 2009, 137:835-848.
17. Toyoshima M, Howie HL, Imakura M, Walsh RM, Annis JE, Chang AN, Frazier J, Chau BN, Loboda A, Linsley PS, et al. Functional genomics identifies therapeutic targets for MYC-driven cancer. Proc Natl Acad Sci U S A 2012, 109:9545-9550.
18. Astsaturov I, Ratushny V, Sukhanova A, Einarson MB, Bagnyukova T, Zhou Y, Devarajan K, Silverman JS, Tikhmyanova N, Skobeleva N, et al. Synthetic Lethal Screen of an EGFR-Centered Network to Improve Targeted Therapies. Sci Signal 2010, 3:ra67.
19. Wang X, Simon R Identification of potential synthetic lethal genes to p53 using a computational biology approach. BMC Med Genomics 2013, 6:30.
20. Edgar R, Domrachev M, Lash AE Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002, 30:207-210.
21. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455:1069-1075.
22. Hong Y, Downey T, Eu KW, Koh PK, Cheah PY A 'metastasis-prone' signature for early-stage mismatch-repair proficient sporadic colorectal cancer patients and its implications for possible therapeutics. Clin Exp Metastasis 2010, 27:83-90.
23. Farmer H, McCabe N, Lord CJ, Tutt ANJ, Johnson DA, Richardson TB, Santarosa M, Dillion KJ, Hickson I, Knights C, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2010, 434:917-921.
24. Storey JD, Tibshirani R Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 2003, 100:9440-9445.
25. Su JL, Shih JY, Yen ML, Jeng YM, Chang CC, Hsieh CY, Wei LH, Yang PC, Kuo ML Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma. Cancer Res 2004, 64:554-564.
26. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007, 318:1108-1113.
27. -/- cells identifies CID1340132 as a novel compound that induces apoptosis in PTEN and PIK3CA mutant human cancer cells. J Biomol Screen 2011, 16:383-393.
28. Martin SA, McCabe N, Mullarkey M, Cummins R, Burgess DJ, Nakabeppu Y, Oka S, Kay E, Lord CJ, Ashworth A DNA Polymerases as Potential Therapeutic Targets for Cancers Deficient in the DNA Mismatch Repair Proteins MSH2 or MLH1. Cancer Cell 2010, 17:235-248.
29. Li G, Yin H, Kuret J Casein kinase 1 delta phosphorylates tau and disrupts its binding to microtubules. J Biol Chem 2004, 279:15938-15945.
30. Callahan JF, Burgess JL, Fornwald JA, Gaster LM, Harling JD, Harrington FP, Heer J, Kwon C, Lehr R, Mathur A, et al. Identification of novel inhibitors of the transforming growth factor beta1 (TGF-beta1) type 1, receptor (ALK5). J Med Chem 2002, 45:999-1001.
31. Bonato V, Baladandayuthapani V, Broom BM, Sulman EP, Aldape KD, Do KA Bayesian ensemble methods for survival prediction in gene expression data. Bioinformatics 2011, 27:359-367.
32. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9:189-198.
33. Yu SL, Chen HY, Chang GC, Chen CY, Chen HW, Singh S, Cheng CL, Yu CJ, Lee YC, Chen HS, et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 2008, 13:48-57.
34. Presson AP, Yoon NK, Bagryanova L, Mah V, Alavi M, Maresh EL, Rajasekaran AK, Goodglick L, Chia D, Horvath S Protein expression based multimarker analysis of breast cancer samples. BMC Cancer 2011, 11:230.
35. Nikitin AY, Liu CY, Flesken-Nikitin A, Chen CF, Chen PL, Lee WH Cell lineage-specific effects associated with multiple deficiencies of tumor susceptibility genes in Msh2-/-Rb+/- mice. Cancer Res 2002, 62:5134-5138.
36. Gudkov AV, Komarova EA Pathologies associated with the p53 response. Cold Spring Harb Perspect Biol 2010, 2:a001180.
37. Behrend L, Milne DM, Stoter M, Deppert W, Campbell LE, Meek DW, Knippschild U IC261, a specific inhibitor of the protein kinases casein kinase 1-delta and -epsilon, triggers the mitotic checkpoint and induces p53-dependent postmitotic effects. Oncogene 2000, 19:5303-5313.
38. Cheong JK, Nguyen TH, Wang H, Tan P, Voorhoeve PM, Lee SH, Virshup DM Oncogene 2011, 30:2558-2569.
39. Grigoryan T, Wend P, Klaus A, Birchmeter W Deciphering the function of canonical Wnt signals in development and disease: conditional loss- and gain-of-function mutations of beta-catenin in mice. Genes Dev 2008, 22:2308-2341.
40. Rivlin N, Brosh R, Oren M, Rotter V Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis. Genes Cancer 2011, 2:466-474.
41. Kim NH, Kim HS, Kim NG, Lee I, Choi HS, Li XY, Kang SE, Cha SY, Ryu JK, Na JM, et al. p53 and microRNA-34 are suppressors of canonical Wnt signaling. Sci Signal 2011, 4:ra71.
42. Sadanandam A, Lyssiotis CA, Homicsko A, Collisson EA, Gibb WJ, Wullschleger S, et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med 2013, 19:619-625.
43. Kosari F., Ida C.M., Aubry M.C., Yang L., Kovtun I.V., Klein J.L., Li Y., Erdogan S., Tomaszek S.C., Murphy S.J., et al. ASCL1 and RET expression defines a clinically relevant subgroup of lung adenocarcinoma characterized by neuroendocrine differentiation. Oncogene 2013, Prepublished on 2013/09/16 as http://dx.doi.org/10.1038/onc.2013.359.